Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Treg Cells in Ulcerative Colitis
NCT04691232Phase 1Completed
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Feb 2021
- Primary completion
- Apr 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous regulatory T cells in ulcerative colitis (UC), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Primary endpoint: Maximal Tolerated Dose at 4 weeks. Started Feb 2021; status: completed.
02
Drugs
autologous regulatory T cells
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04691232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04691232.